MX2021007356A - Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos. - Google Patents

Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos.

Info

Publication number
MX2021007356A
MX2021007356A MX2021007356A MX2021007356A MX2021007356A MX 2021007356 A MX2021007356 A MX 2021007356A MX 2021007356 A MX2021007356 A MX 2021007356A MX 2021007356 A MX2021007356 A MX 2021007356A MX 2021007356 A MX2021007356 A MX 2021007356A
Authority
MX
Mexico
Prior art keywords
angptl3
methods
disclosed
same
antibodies
Prior art date
Application number
MX2021007356A
Other languages
English (en)
Inventor
Oliver Schroeder
Jonathan Wesley Day
Qing Chai
Robert John Konrad
Yuewei Qian
Robert William Siegel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021007356A publication Critical patent/MX2021007356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A61B5/02108—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics
    • A61B5/02125—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics of pulse wave propagation time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02438—Detecting, measuring or recording pulse rate or heart rate with portable devices, e.g. worn by the patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02444—Details of sensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6802—Sensor mounted on worn items
    • A61B5/681—Wristwatch-type devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6843—Monitoring or controlling sensor contact pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

Se divulgan complejos de proteínas similares a la angiopoyetina (ANGPTL) 3/8 y anticuerpos, donde los anticuerpos se fijan a y, por lo tanto, neutralizan los complejos de ANGPTL3/8. También se divulgan composiciones farmacéuticas que incluyen uno o más de los anticuerpos anti-complejo de ANGPTL3/8 en la presente en un portador aceptable desde el punto de vista farmacéutico. También se divulgan métodos para elaborarlos y usarlos, especialmente para aumentar la actividad de la lipoproteína lipasa y disminuir los triglicéridos. De esta manera, los compuestos y las composiciones se pueden usar en el tratamiento de enfermedades y trastornos relacionados con el metabolismo de lípidos y relacionados con el metabolismo de la glucosa.
MX2021007356A 2018-12-21 2019-12-13 Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos. MX2021007356A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783265P 2018-12-21 2018-12-21
US201862783260P 2018-12-21 2018-12-21
PCT/US2019/066261 WO2020131624A1 (en) 2018-12-21 2019-12-13 Anti-angptl3/8 complex antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
MX2021007356A true MX2021007356A (es) 2021-07-15

Family

ID=69160392

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007356A MX2021007356A (es) 2018-12-21 2019-12-13 Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos.
MX2021007357A MX2021007357A (es) 2018-12-21 2019-12-13 Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007357A MX2021007357A (es) 2018-12-21 2019-12-13 Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos.

Country Status (13)

Country Link
US (4) US11242383B2 (es)
EP (2) EP3898670A2 (es)
JP (3) JP7241883B2 (es)
KR (2) KR20210093995A (es)
CN (2) CN113454228A (es)
AU (2) AU2019405442B2 (es)
BR (2) BR112021011941A2 (es)
CA (2) CA3124413A1 (es)
IL (2) IL283611A (es)
MA (2) MA54527A (es)
MX (2) MX2021007356A (es)
TW (2) TWI747098B (es)
WO (2) WO2020131624A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060491B1 (en) 1999-11-18 2006-06-13 Pioneer Hi-Bred International, Inc. Polynucleotides encoding novel BT toxin receptors from lepidopteran insects
US6664387B2 (en) 2001-01-17 2003-12-16 Korea Kumho Petrochemical Co., Ltd. Expression cassette and plasmid for strong constitutive gene expression and the use thereof
AU2002348286B2 (en) * 2001-11-16 2008-04-03 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 Angptl3
ES2384973T3 (es) 2003-02-14 2012-07-16 Biogen Idec Ma Inc. Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas
CA2526686A1 (en) 2004-12-11 2006-06-11 Sungene Gmbh Expression cassettes for regulating meristem-preferential or meristem-specific expression in plants
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
MX2010001693A (es) * 2007-08-31 2010-03-11 Boehringer Ingelheim Int Composicion pulverizable que contiene extracto de hojas de parra rojas.
US20120178693A1 (en) * 2009-08-28 2012-07-12 Bayer Healthcare Llc Cofactors for Thrombin Activation of Factor VII and Uses Thereof
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
JP6437913B2 (ja) * 2012-08-17 2018-12-12 モルフォシス・アーゲー 複合体特異的抗体及び抗体断片並びにその使用
CN104928272A (zh) * 2014-03-19 2015-09-23 财团法人工业技术研究院 融合多肽、编码它的核酸分子以及使用它产生衣康酸的方法
WO2016054494A1 (en) * 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CA3020175A1 (en) * 2016-04-08 2017-10-12 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor
JP7133551B2 (ja) 2016-11-17 2022-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法

Also Published As

Publication number Publication date
KR20210093995A (ko) 2021-07-28
US20220110537A1 (en) 2022-04-14
CA3124413A1 (en) 2020-06-25
US20200199212A1 (en) 2020-06-25
JP2022514763A (ja) 2022-02-15
TW202039550A (zh) 2020-11-01
KR20210093994A (ko) 2021-07-28
IL283611A (en) 2021-07-29
MA54527A (fr) 2021-10-27
WO2020131606A9 (en) 2020-11-12
JP2022514765A (ja) 2022-02-15
KR102656910B1 (ko) 2024-04-16
JP2023071918A (ja) 2023-05-23
US20210147530A1 (en) 2021-05-20
CN113454228A (zh) 2021-09-28
CA3124315A1 (en) 2020-06-25
US11242383B2 (en) 2022-02-08
CN113453754B (zh) 2024-05-03
WO2020131624A1 (en) 2020-06-25
BR112021011910A2 (pt) 2021-09-08
MA54529A (fr) 2021-10-27
US10919959B2 (en) 2021-02-16
WO2020131606A3 (en) 2020-07-30
BR112021011941A2 (pt) 2021-09-14
TWI749421B (zh) 2021-12-11
US20200199213A1 (en) 2020-06-25
WO2020131606A2 (en) 2020-06-25
TWI747098B (zh) 2021-11-21
US11492395B2 (en) 2022-11-08
CA3124315C (en) 2024-01-02
IL284069A (en) 2021-08-31
CN113453754A (zh) 2021-09-28
AU2019405442A1 (en) 2021-06-17
AU2019405442B2 (en) 2023-02-09
EP3898670A2 (en) 2021-10-27
JP7394855B2 (ja) 2023-12-08
TW202039551A (zh) 2020-11-01
MX2021007357A (es) 2021-07-15
EP3897829A1 (en) 2021-10-27
JP7241883B2 (ja) 2023-03-17
AU2019406505A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
EA202190059A1 (ru) Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MA39342A1 (fr) Anticorps il -21
MX2022003306A (es) Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021007356A (es) Anticuerpos anti-complejo de angptl3/8 y metodos de uso de estos.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.
MX2021008941A (es) Moduladores gpr35.
WO2020086479A9 (en) Dosing
MX2021008188A (es) Compuestos de anandamida.